AAV with CMV7 promoter driven Cre Inducible VChR1-ECFP
This AAV expresses DIO-VChR1-ECFP driven by an ubiquitous CMV7 promoter.
The CMV7 promoter is about 0.35 kb in length and is a shortened version of the commonly used CMV promoter. CMV7 has a truncated version of the CMV enhancer. When tested in several cell lines, this promoter provides an expression level that is about 3-5 fold lower than that of the original 0.6Kb CMV promoter.
Volvox channelrhodopsin-1 (VChR1) is from the multicellular green alga Volvox carteri. VChR1 has a similar functionality as hChR2 but with a different excitation spectrum towards green light, and shows action potential firing with 589 nm light.
In the DIO scenario, the transgene of interest is inserted in reverse orientation relative to the 5′ promoter and is flanked by oppositely oriented loxP and lox2272 sites. In the absence of Cre expression, the transgene will not be produced. In the presence of Cre expression, the transgene will be “FLip-EXchanged” or FLEXed, leading to expression of the transgene. This is due to a permanent Cre-mediated recombination/inversion of the flanked transgene. This arrangement is called DIO (double-floxed inverse ORF), Cre-ON, Flex-rev (reverse), Flex-ON/FlexON, or DIO-AAV/AAV-DIO (double-floxed inverse ORF in AAV).
Ready-to-use AAV expressing DIO-VChR1-ECFP driven by an ubiquitous CMV7 promoter. Available in AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ and other serotypes.